화학요법제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for chemotherapy drugs. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global chemotherapy drugs market from 2025 to 2032.

Key Insights:

• Chemotherapy Drugs Market Size (2025E): US$ 56.1Bn
• Projected Market Value (2032F):US$ 102.5Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 9.0%

Chemotherapy Drugs Market - Report Scope:

Chemotherapy drugs are essential in cancer treatment, working by targeting and eliminating rapidly dividing cancer cells. These drugs are used in combination with other treatments, including surgery, radiation therapy, and immunotherapy, to enhance patient outcomes. The chemotherapy drugs market caters to hospitals, specialty cancer centers, and homecare settings, offering a range of drug types, including alkylating agents, antimetabolites, mitotic inhibitors, and topoisomerase inhibitors. Market growth is driven by increasing cancer prevalence, rising healthcare expenditures, and advancements in drug formulations, enhancing treatment efficacy and reducing side effects.

Market Growth Drivers:

The global chemotherapy drugs market is propelled by several key factors, including the increasing global burden of cancer, advancements in drug development, and the rising demand for targeted therapies. The growing aging population, coupled with lifestyle-related risk factors such as smoking, poor diet, and environmental pollution, contributes to the rising incidence of cancer, fueling the demand for chemotherapy treatments. Additionally, the development of combination therapies and personalized medicine has improved patient outcomes, leading to wider adoption of chemotherapy drugs. Government initiatives aimed at improving cancer care infrastructure and increasing research funding further drive market expansion.

Market Restraints:

Despite promising growth prospects, the chemotherapy drugs market faces challenges related to drug toxicity, high treatment costs, and stringent regulatory requirements. The adverse side effects associated with chemotherapy, such as nausea, hair loss, and immune suppression, often lead to treatment discontinuation, impacting market adoption. Additionally, the high cost of chemotherapy drugs and the financial burden on patients, particularly in low- and middle-income countries, pose significant barriers to market penetration. Regulatory challenges, including lengthy drug approval processes and compliance with stringent safety guidelines, further hinder market expansion. Addressing these challenges requires increased investment in supportive care, cost-effective drug formulations, and regulatory harmonization.

Market Opportunities:

The chemotherapy drugs market presents significant growth opportunities driven by technological advancements, expanding healthcare access, and increasing R&D investments. The development of targeted chemotherapy drugs with reduced side effects and enhanced efficacy is a key area of innovation. Additionally, the growing adoption of biosimilars and generic chemotherapy drugs is expected to improve affordability and expand market reach. Emerging markets in Asia-Pacific and Latin America offer lucrative opportunities due to rising healthcare infrastructure investments and increasing awareness about cancer treatment options. Strategic collaborations, partnerships with biotechnology firms, and continuous advancements in drug delivery mechanisms are essential for companies to capitalize on these opportunities and maintain market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the chemotherapy drugs market globally?
• Which drug types and applications are driving chemotherapy adoption across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the chemotherapy drugs market?
• Who are the key players contributing to the chemotherapy drugs market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global chemotherapy drugs market?

Competitive Intelligence and Business Strategy:

Leading players in the global chemotherapy drugs market, including Pfizer Inc., Roche Holding AG, Bristol-Myers Squibb Company, and Novartis AG, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced chemotherapy solutions, including targeted therapies, antibody-drug conjugates, and nanoparticle-based drug delivery systems, catering to diverse patient needs and clinical requirements. Collaborations with research institutions, hospitals, and regulatory agencies facilitate market access and promote drug adoption. Moreover, emphasis on clinical research, precision medicine, and patient-centric approaches fosters market growth and enhances treatment outcomes in the evolving oncology landscape.

Key Companies Profiled:

• Pfizer Inc.
• Roche Holding AG
• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• Sanofi S.A.
• Merck & Co., Inc.
• AstraZeneca PLC
• Amgen Inc.
• Bayer AG

Key Segments of Chemotherapy Drugs Industry Research

By Drug Class:

• Alkylating Agents
• Antimetabolites
• Anti-tumour Antibiotics
• Topoisomerase Inhibitors
• Mitotic Inhibitors
• Plant Alkaloids
• Corticosteroids
• Miscellaneous Antineoplastic

By Indication:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma
• Ovarian Cancer
• Pancreatic Cancer

By Route of Administration:

• Oral
• Parenteral

By Dosage Form:

• Capsules/Tablets
• Injections

By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Oncology Clinics & Infusion Centers

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Chemotherapy Drugs Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Regulatory Landscape
• 3.3. Disease Epidemiology
• 3.4. Value Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Chemotherapy Drugs Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2032
• 4.3. Global Chemotherapy Drugs Market Outlook: Drug Class
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2024
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
    • 4.3.3.1. Alkylating Agents
    • 4.3.3.2. Antimetabolites
    • 4.3.3.3. Anti-tumour Antibiotics
    • 4.3.3.4. Topoisomerase Inhibitors
    • 4.3.3.5. Mitotic Inhibitors
    • 4.3.3.6. Plant Alkaloids
    • 4.3.3.7. Corticosteroids
    • 4.3.3.8. Miscellaneous Antineoplastic
  • 4.3.4. Market Attractiveness Analysis: Drug Class
• 4.4. Global Chemotherapy Drugs Market Outlook: Indication
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
  • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
    • 4.4.3.1. Lung Cancer
    • 4.4.3.2. Breast Cancer
    • 4.4.3.3. Colorectal Cancer
    • 4.4.3.4. Prostate Cancer
    • 4.4.3.5. Leukemia
    • 4.4.3.6. Lymphoma
    • 4.4.3.7. Ovarian Cancer
    • 4.4.3.8. Pancreatic Cancer
    • 4.4.3.9. Others
  • 4.4.4. Market Attractiveness Analysis: Indication
• 4.5. Global Chemotherapy Drugs Market Outlook: Route of Administration
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2024
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
    • 4.5.3.1. Oral
    • 4.5.3.2. Parenteral
    • 4.5.3.3. Others
  • 4.5.4. Market Attractiveness Analysis: Route of Administration
• 4.6. Global Chemotherapy Drugs Market Outlook: Dosage Form
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Bn) Analysis, By Dosage Form, 2019-2024
  • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
    • 4.6.3.1. Capsules/Tablets
    • 4.6.3.2. Injections
    • 4.6.3.3. Others
  • 4.6.4. Market Attractiveness Analysis: Dosage Form
• 4.7. Global Chemotherapy Drugs Market Outlook: Distribution Channel
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
    • 4.7.3.1. Retail Pharmacies
    • 4.7.3.2. Hospital Pharmacies
    • 4.7.3.3. Oncology Clinics & Infusion Centers
    • 4.7.3.4. Others
  • 4.7.4. Market Attractiveness Analysis: Distribution Channel

5. Global Chemotherapy Drugs Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Chemotherapy Drugs Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Drug Class
  • 6.2.3. By Indication
  • 6.2.4. By Route of Administration
  • 6.2.5. By Dosage Form
  • 6.2.6. By Distribution Channel
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 6.4.1. Alkylating Agents
  • 6.4.2. Antimetabolites
  • 6.4.3. Anti-tumour Antibiotics
  • 6.4.4. Topoisomerase Inhibitors
  • 6.4.5. Mitotic Inhibitors
  • 6.4.6. Plant Alkaloids
  • 6.4.7. Corticosteroids
  • 6.4.8. Miscellaneous Antineoplastic
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 6.5.1. Lung Cancer
  • 6.5.2. Breast Cancer
  • 6.5.3. Colorectal Cancer
  • 6.5.4. Prostate Cancer
  • 6.5.5. Leukemia
  • 6.5.6. Lymphoma
  • 6.5.7. Ovarian Cancer
  • 6.5.8. Pancreatic Cancer
  • 6.5.9. Others
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 6.6.1. Oral
  • 6.6.2. Parenteral
  • 6.6.3. Others
• 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 6.7.1. Capsules/Tablets
  • 6.7.2. Injections
  • 6.7.3. Others
• 6.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 6.8.1. Retail Pharmacies
  • 6.8.2. Hospital Pharmacies
  • 6.8.3. Oncology Clinics & Infusion Centers
  • 6.8.4. Others
• 6.9. Market Attractiveness Analysis

7. Europe Chemotherapy Drugs Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Drug Class
  • 7.2.3. By Indication
  • 7.2.4. By Route of Administration
  • 7.2.5. By Dosage Form
  • 7.2.6. By Distribution Channel
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 7.4.1. Alkylating Agents
  • 7.4.2. Antimetabolites
  • 7.4.3. Anti-tumour Antibiotics
  • 7.4.4. Topoisomerase Inhibitors
  • 7.4.5. Mitotic Inhibitors
  • 7.4.6. Plant Alkaloids
  • 7.4.7. Corticosteroids
  • 7.4.8. Miscellaneous Antineoplastic
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 7.5.1. Lung Cancer
  • 7.5.2. Breast Cancer
  • 7.5.3. Colorectal Cancer
  • 7.5.4. Prostate Cancer
  • 7.5.5. Leukemia
  • 7.5.6. Lymphoma
  • 7.5.7. Ovarian Cancer
  • 7.5.8. Pancreatic Cancer
  • 7.5.9. Others
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 7.6.1. Oral
  • 7.6.2. Parenteral
  • 7.6.3. Others
• 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 7.7.1. Capsules/Tablets
  • 7.7.2. Injections
  • 7.7.3. Others
• 7.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 7.8.1. Retail Pharmacies
  • 7.8.2. Hospital Pharmacies
  • 7.8.3. Oncology Clinics & Infusion Centers
  • 7.8.4. Others
• 7.9. Market Attractiveness Analysis

8. East Asia Chemotherapy Drugs Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Drug Class
  • 8.2.3. By Indication
  • 8.2.4. By Route of Administration
  • 8.2.5. By Dosage Form
  • 8.2.6. By Distribution Channel
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 8.4.1. Alkylating Agents
  • 8.4.2. Antimetabolites
  • 8.4.3. Anti-tumour Antibiotics
  • 8.4.4. Topoisomerase Inhibitors
  • 8.4.5. Mitotic Inhibitors
  • 8.4.6. Plant Alkaloids
  • 8.4.7. Corticosteroids
  • 8.4.8. Miscellaneous Antineoplastic
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 8.5.1. Lung Cancer
  • 8.5.2. Breast Cancer
  • 8.5.3. Colorectal Cancer
  • 8.5.4. Prostate Cancer
  • 8.5.5. Leukemia
  • 8.5.6. Lymphoma
  • 8.5.7. Ovarian Cancer
  • 8.5.8. Pancreatic Cancer
  • 8.5.9. Others
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 8.6.1. Oral
  • 8.6.2. Parenteral
  • 8.6.3. Others
• 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 8.7.1. Capsules/Tablets
  • 8.7.2. Injections
  • 8.7.3. Others
• 8.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 8.8.1. Retail Pharmacies
  • 8.8.2. Hospital Pharmacies
  • 8.8.3. Oncology Clinics & Infusion Centers
  • 8.8.4. Others
• 8.9. Market Attractiveness Analysis

9. South Asia & Oceania Chemotherapy Drugs Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Drug Class
  • 9.2.3. By Indication
  • 9.2.4. By Route of Administration
  • 9.2.5. By Dosage Form
  • 9.2.6. By Distribution Channel
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 9.4.1. Alkylating Agents
  • 9.4.2. Antimetabolites
  • 9.4.3. Anti-tumour Antibiotics
  • 9.4.4. Topoisomerase Inhibitors
  • 9.4.5. Mitotic Inhibitors
  • 9.4.6. Plant Alkaloids
  • 9.4.7. Corticosteroids
  • 9.4.8. Miscellaneous Antineoplastic
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 9.5.1. Lung Cancer
  • 9.5.2. Breast Cancer
  • 9.5.3. Colorectal Cancer
  • 9.5.4. Prostate Cancer
  • 9.5.5. Leukemia
  • 9.5.6. Lymphoma
  • 9.5.7. Ovarian Cancer
  • 9.5.8. Pancreatic Cancer
  • 9.5.9. Others
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 9.6.1. Oral
  • 9.6.2. Parenteral
  • 9.6.3. Others
• 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 9.7.1. Capsules/Tablets
  • 9.7.2. Injections
  • 9.7.3. Others
• 9.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 9.8.1. Retail Pharmacies
  • 9.8.2. Hospital Pharmacies
  • 9.8.3. Oncology Clinics & Infusion Centers
  • 9.8.4. Others
• 9.9. Market Attractiveness Analysis

10. Latin America Chemotherapy Drugs Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Drug Class
  • 10.2.3. By Indication
  • 10.2.4. By Route of Administration
  • 10.2.5. By Dosage Form
  • 10.2.6. By Distribution Channel
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 10.4.1. Alkylating Agents
  • 10.4.2. Antimetabolites
  • 10.4.3. Anti-tumour Antibiotics
  • 10.4.4. Topoisomerase Inhibitors
  • 10.4.5. Mitotic Inhibitors
  • 10.4.6. Plant Alkaloids
  • 10.4.7. Corticosteroids
  • 10.4.8. Miscellaneous Antineoplastic
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 10.5.1. Lung Cancer
  • 10.5.2. Breast Cancer
  • 10.5.3. Colorectal Cancer
  • 10.5.4. Prostate Cancer
  • 10.5.5. Leukemia
  • 10.5.6. Lymphoma
  • 10.5.7. Ovarian Cancer
  • 10.5.8. Pancreatic Cancer
  • 10.5.9. Others
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 10.6.1. Oral
  • 10.6.2. Parenteral
  • 10.6.3. Others
• 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 10.7.1. Capsules/Tablets
  • 10.7.2. Injections
  • 10.7.3. Others
• 10.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 10.8.1. Retail Pharmacies
  • 10.8.2. Hospital Pharmacies
  • 10.8.3. Oncology Clinics & Infusion Centers
  • 10.8.4. Others
• 10.9. Market Attractiveness Analysis

11. Middle East & Africa Chemotherapy Drugs Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Drug Class
  • 11.2.3. By Indication
  • 11.2.4. By Route of Administration
  • 11.2.5. By Dosage Form
  • 11.2.6. By Distribution Channel
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 11.4.1. Alkylating Agents
  • 11.4.2. Antimetabolites
  • 11.4.3. Anti-tumour Antibiotics
  • 11.4.4. Topoisomerase Inhibitors
  • 11.4.5. Mitotic Inhibitors
  • 11.4.6. Plant Alkaloids
  • 11.4.7. Corticosteroids
  • 11.4.8. Miscellaneous Antineoplastic
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 11.5.1. Lung Cancer
  • 11.5.2. Breast Cancer
  • 11.5.3. Colorectal Cancer
  • 11.5.4. Prostate Cancer
  • 11.5.5. Leukemia
  • 11.5.6. Lymphoma
  • 11.5.7. Ovarian Cancer
  • 11.5.8. Pancreatic Cancer
  • 11.5.9. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 11.6.1. Oral
  • 11.6.2. Parenteral
  • 11.6.3. Others
• 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 11.7.1. Capsules/Tablets
  • 11.7.2. Injections
  • 11.7.3. Others
• 11.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 11.8.1. Retail Pharmacies
  • 11.8.2. Hospital Pharmacies
  • 11.8.3. Oncology Clinics & Infusion Centers
  • 11.8.4. Others
• 11.9. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. F. Hoffmann-La Roche Ltd
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Product Types
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Celgene Corp
  • 12.3.3. Novartis AG
  • 12.3.4. Bristol-Myers Squibb Co
  • 12.3.5. Johnson & Johnson
  • 12.3.6. Sanofi
  • 12.3.7. Pfizer Inc.
  • 12.3.8. Eli Lilly & Company
  • 12.3.9. ImClone Systems Inc.
  • 12.3.10. GlaxoSmithKline
  • 12.3.11. AstraZeneca
  • 12.3.12. Schering-Plough
  • 12.3.13. Boehringer Ingelheim
  • 12.3.14. Bristol-Myers Squibb
  • 12.3.15. Teva Pharmaceuticals Industries
  • 12.3.16. E. Hoffmann-La Roche Ltd
  • 12.3.17. Merck & Co. Inc.
  • 12.3.18. Chemo Espana SL
  • 12.3.19. Amgen Inc
  • 12.3.20. Bayer AG
  • 12.3.21. Takeda Pharmaceutical Company Limited

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations